Editorial Comment on: Cizolirtine Citrate, an Effective Treatment for Symptomatic Patients with Urinary Incontinence Secondary to Overactive Bladder: A Pilot Dose-Finding Study

European Urology

Volumn 56, Issue 1, 2009, Pages 191-

  May, Florian ^a   Bauer, Ricarda ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIZOLIRTINE; PLACEBO; CALCITONIN GENE RELATED PEPTIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; PYRAZOLE DERIVATIVE; SUBSTANCE P;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MULTICENTER STUDY; NOTE; OVERACTIVE BLADDER; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; URINE INCONTINENCE; COMPARATIVE STUDY; FEMALE; SECRETION;

CALCITONIN GENE-RELATED PEPTIDE; FEMALE; HUMANS; MUSCARINIC ANTAGONISTS; PYRAZOLES; SUBSTANCE P; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 67349219450     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.04.028     Document Type: Note

References (3)

1. Chapple C., Khullar V., Gabriel Z., and Dooley J.A. The effects of antimuscarinic treatment in overactive bladder: a systematic review and meta-analysis. Eur Urol 48 (2005) 5-26
2. Hampel C. Long-term management of overactive bladder with antimuscarinic agents. Eur Urol Suppl 6 (2007) 432-437
3. Martínez-García R., Abadías M., Arañó P., et al. Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose finding study. Eur Urol 56 (2009) 184-192